The cell and gene therapy CRO market is currently valued at $713 million in 2022 and is projected to grow at a compounded annual growth rate (CAGR) of 18% during the forecast period. Cell and gene therapy has demonstrated its potential in treating complex and rare diseases, including those for which effective treatments are currently lacking.

In the case of cell therapy, human cells are transplanted to repair or replace damaged cells or tissues, enabling the alteration or restoration of specific sets of cells. These cells may originate from the patient (autologous cells) or a donor (allogeneic cells). On the other hand, gene therapy aims to address underlying genetic issues to treat and prevent diseases by introducing, inactivating, or replacing genes within cells, either inside or outside the body. It’s important to note that some therapeutic interventions can be classified as both cell and gene therapies. These therapies typically involve gene modification in specific cell types before their insertion into the patient’s body.

Currently, the cell and gene therapy industry stands as one of the fastest-growing therapeutic segments and has already brought about significant disruptions in the biopharmaceutical domain. To date, the Food and Drug Administration (FDA) in the US has approved 23 cell and gene therapies, with more than 1,000 Investigational New Drug (IND) applications filed for candidates undergoing evaluation in ongoing clinical studies. This remarkable progress highlights the promising potential and scientific advancements of these groundbreaking drug candidates.

Key Market Segments
Area of Expertise
? Cell Therapies
? Gene Therapies

Scale of Operation
? Clinical
? Preclinical and Discovery

Therapeutic Areas
? Oncological Disorders
? Neurological Disorders
? Cardiovascular Disorders
? Infectious Diseases
? Metabolic Disorders
? Autoimmune Disorders
? Blood Disorders
? Rare / Genetic Disorders
? Ophthalmological Disorders
? Other Disorders

Geographical Regions
? North America
? Europe
? Asia-Pacific
? MENA
? Latin America
? Rest of the World

Research Coverage:
? The report studies the cell and gene therapy CRO market by area of expertise, scale of operation, therapeutic area and key geographical regions
? The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
? The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
? The report forecasts the revenue of market segments with respect to major regions.
? A comprehensive overview of the cell and gene therapy CRO market, including details on year of establishment, company size (number of employees), location of headquarters, areas of expertise (cell therapy and gene therapy), scale of operation (discovery, preclinical, clinical, and commercial), and types of services offered, encompassing preclinical services, clinical services, regulatory services, and general support services.
? An in-depth analysis of common business models adopted by the biopharmaceutical industry for outsourcing cell and gene therapies, including factors that drive developers toward outsourcing and key considerations for sponsors when choosing CROs at different phases of the drug development process.
? Detailed profiles of companies based in North America, Europe, and Asia-Pacific offering contract research services for cell and gene therapies at both preclinical and clinical scales of operation. Each profile includes an overview of the company, information about their service portfolio, recent developments, and future outlook.
? A benchmark analysis of various players in the cell and gene therapy CRO market, highlighting their expertise across different services related to cell and gene therapy development, allowing companies to assess their capabilities relative to their peers.
? Analysis of recent collaborations within the cell and gene therapy contract research industry, covering parameters like the year of partnership, partnership type, area of expertise, the most active players (based on the number of deals), and regional distribution of partnership activity in the cell and gene therapy CRO market from 2015 to 2022.
? A detailed examination of mergers and acquisitions that occurred in the cell and gene therapy CRO market from 2015 to 2022, considering factors such as year, agreement type, area of expertise, geographical location of the companies, and key value drivers.
? An acquisition target analysis based on the historical activity of companies acquiring other firms since 2015, offering insights for industry stakeholders to identify potential acquisition targets.
? A list of over 310 cell therapy companies anticipated to partner with cell therapy CROs. These companies were selected based on developer strength, pipeline strength, and availability of other cell therapy capabilities.
? An in-depth analysis of nearly 235 gene therapy companies expected to partner with gene therapy CROs, selected based on developer strength, pipeline strength, and availability of other gene therapy capabilities.
? An analysis of completed, ongoing, and planned clinical studies for various cell and gene therapies based on parameters such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (based on the number of trials conducted), therapeutic area, and key geographical regions.
? A detailed analysis of the total cost of ownership for large/very large cell and gene therapy contract research organizations, estimating direct and indirect expenses over a 20-year period.
? A discussion of trends, key drivers, and challenges in the cell and gene therapy CRO industry under a SWOT framework, assessing the relative impact of each SWOT parameter on the overall cell and gene therapies research services sector.

Key Benefits of Buying this Report
? The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
? Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
? The report provides stakeholders with a pulse on the container closure integrity testing market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
? You will get access to complimentary PPT insights and excel data packs / dynamic dashboards to easily navigate through complex analyses / charts.

Key Market Companies
? Altasciences
? Allucent (formerly known as CATO SMS)
? Accelera
? Charles River Laboratories
? CMIC Group
? Creative Biolabs
? Evotec
? ICON
? IQVIA
? Labcorp
? Medpace
? PPD
? Precision for Medicine
? QPS
? Syneos Health